Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

Nanomedicine has revolutionized cancer therapeutic strategies but has not completely
changed the outcomes of tricky tumors that evolve a sophisticated immunosuppressive …

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …

Thrombocytopenia is a major complication in a subset of patients with multiple myeloma
(MM). However, little is known about its development and significance during MM. Here, we …

Simple Summary Tumor-associated macrophages (TAM) represent a leading component of
the tumor microenvironment in hematologic malignancies. TAM could display antitumor …

Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma
(MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant …

Multiple myeloma remains an incurable disease, and the cellular and molecular evolution
from precursor conditions, including monoclonal gammopathy of undetermined significance …

Backgrounds Decreased cytotoxicity of natural killer (NK) cells has been shown in multiple
myeloma (MM). However, the underlying molecular mechanisms remain unclear. Here, by …

Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …